Profound Medical Corp.

TSX:PRN.TO

Medical - Devices

Healthcare
$9.83 +1.18%

+$0.11 today

Market cap
$360.04M
Beta
0.52
P/E (TTM)
-6.3
EPS (TTM)
-$1.07
52W Low $5.23High $12.40

Volume 0.00M

Average 0.01M

PRN.TO Revenue

Total income from selling goods and services before any costs are deducted; the top line of the income statement.

Profound Medical Corp.TSX: PRN.TO

Revenue · Q1 FY2026 · quarter ended Mar 2026

Revenue growth accelerates

Q1 FY2026 revenue of $5.25M rose 100.3% year over year, ahead of the +64.7% change in trailing-twelve-month revenue. Sequentially, it fell 13.5% from the prior quarter. Over 3 fiscal years it compounded at +34.8% a year.

Context

  • Revenue increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether revenue reaches the consensus estimate from 4 analysts of $25.71M (+57.0%) for the fiscal year ending Dec 2026, a step up from the +53.4% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$5.25M-13.5% QoQ
Last fiscal yearDec 2025
$16.38M+53.4% YoY
LTMMar 2026
$18.76M+64.7% YoY
Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+100.3%+114.7%+14.5 pp
1 year+53.4%+57.0%+3.6 pp
3-year CAGR+34.8%+56.9%+22.0 pp
5-year CAGR+53.5%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Revenue history

USD · from the income statement

Latest · FY2025
16.38M USD
Year-over-year change
+53.4%
4-year CAGR
+24.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Revenue vs competitors

How PRN.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
  • Its year-over-year change of +64.7% is the highest of 5, against a peer median of +1.2%.
  • Over three fiscal years its annual growth of +34.8% compares with a peer median of -1.9%.
PRN.TO Competitors
Revenue for PRN.TO and competitors
Company Period LTM YoY 3-year CAGR
CRRX.TOCareRx CorporationLTM Mar 2026CA$374.61M CAD+2.2%-1.0%
DR.TOMedical Facilities CorporationLTM Mar 2026$305.39M USD+0.1%-15.2%
XLY.TOAuxly Cannabis Group Inc.LTM Mar 2026CA$158.57M CAD+22.2%+17.0%
HLS.TOHLS Therapeutics Inc.LTM Mar 2026$55.76M USD-1.8%-2.8%
PRN.TOProfound Medical Corp.LTM Mar 2026$18.76M USD+64.7%+34.8%
EPRX.TOEupraxia Pharmaceuticals Inc.LTM Mar 2026$0 USD——
Peer median (excluding PRN.TO) —+1.2%-1.9%

Competitors are the stored peer set for PRN.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue6.87M6.68M7.2M10.68M16.38M
Cost of Revenue3.92M3.66M2.82M3.64M4.79M
Gross Profit2.95M3.02M4.38M7.04M11.59M
Gross Margin43.0%45.2%60.9%65.9%70.8%
Research & Development15.28M14.69M14.38M16.97M20.96M
Selling, General & Admin17.97M17.93M18.62M23.13M32.61M
Operating Expenses33.24M32.62M33M40.1M53.57M
Depreciation & Amortization1.88M1.6M929K936K569.8K
EBITDA(28.65M)(26.6M)(27M)(32.13M)(41.41M)
EBITDA Margin-416.8%-398.2%-375.0%-300.8%-252.8%
Operating Income(30.29M)(29.6M)(28.62M)(33.06M)(41.98M)
Operating Margin-440.7%-443.1%-397.5%-309.6%-256.3%
Interest Income205K1.06M1.64M1.44M1.09M
Interest Expense67K168.82K770K00
Other Income / Expenses(303K)1.22M200K5.24M(1.08M)
Income Before Tax(30.59M)(28.38M)(28.7M)(27.82M)(43.06M)
Pre-Tax Margin-445.1%-424.8%-398.6%-260.5%-262.9%
Income Tax Expense105K287K(128K)(2K)256.41K
Net Income(30.7M)(28.67M)(28.57M)(27.82M)(43.32M)
Net Margin-446.7%-429.1%-396.8%-260.4%-264.4%
EPS (Basic)(1.50)(1.38)(1.35)(1.12)(1.43)
EPS (Diluted)(1.50)(1.38)(1.35)(1.12)(1.43)
Weighted Avg Shares20.46M20.77M21.18M24.77M30.23M
Weighted Avg Shares (Diluted)20.47M20.77M21.18M24.77M30.23M

Profound Medical Corp.

TSX:PRN.TO

Intrinsic Alpha fair value

Locked

Current Price

$9.83

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.